QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3127last 7d

512● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1821 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: CRSPSentiment:bullish neutral bearish show all (incl. clickbait)

Investor's Business Daily6d agoneutral

Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance Hike

Zacks6d agobullish

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates

Motley Fool6d agoneutral

Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction

Zacks6d agobullish

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks67d agoneutral

Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?

MarketBeat95d agoneutral

Blue Bird Q3 Earnings Call Highlights

Zacks96d agoneutral

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

Zacks97d agobullish

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

Zacks104d agobullish

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks158d agoneutral

Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?

Insider Monkey169d agoneutral

CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results

Zacks188d agoneutral

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

Simply Wall St.193d agoneutral

Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings Hopes